Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia. It also offers Aricept for the treatment of Alzheimer's disease/dementia with Lewy bodies worldwide; and BELVIQ, an antiobesity agent in the United States. In addition, it develops Halaven, an anticancer agent in the oncology area for use in the treatment of breast cancer in approximately 65 countries and also for use in the treatment of malignant soft tissue sarcoma in 50 countries; and Lenvima, an anticancer agent for use in the treatment of thyroid cancer in Japan, the United States, Europe, and Asia. Further, the company has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in the United States and Europe. It has strategic collaboration with Merck & Co., Inc. for Lenvima in the oncology and dementia fields; and with Ono Pharmaceutical Co., Ltd. for Lenvima and Opdivo combination therapy for the treatment of hepatocellular carcinoma, as well as Collaboration Agreement with Ono Pharmaceutical Co., Ltd. to develop a therapy for treatment of hepatocellular carcinoma. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Industry, Sector and Symbol
Industry Private households
Sub-IndustryN/A
SectorMedical
Phone813-3817-3700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.42 billion
Profitability
Miscellaneous
Employees10,456
OptionableNot Optionable
Eisai (OTCMKTS:ESALY) Frequently Asked Questions
What is Eisai's stock symbol?
Eisai trades on the OTCMKTS under the ticker symbol "ESALY."
How were Eisai's earnings last quarter?
Eisai Co., Ltd (OTCMKTS:ESALY) announced its quarterly earnings results on Monday, February, 4th. The company reported $0.23 EPS for the quarter, missing analysts' consensus estimates of $0.28 by $0.05. The company earned $1.39 billion during the quarter. Eisai had a net margin of 10.19% and a return on equity of 10.16%. View Eisai's Earnings History.
When is Eisai's next earnings date?
What guidance has Eisai issued on next quarter's earnings?
Eisai updated its FY 2019 earnings guidance on Monday, February, 4th. The company provided earnings per share guidance of $1.90-1.90 for the period. The company issued revenue guidance of $5.727-5.727 billion.
Has Eisai been receiving favorable news coverage?
Headlines about ESALY stock have trended somewhat negative on Saturday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eisai earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Eisai's key competitors?
Some companies that are related to Eisai include INDUSTRIA DE DI/ADR (IDEXY), NK Lukoil PAO (LUKOY), VINCI S A/ADR (VCISY), Iberdrola (IBDRY), JAPAN TOB INC/ADR (JAPAY), Sun Hung Kai Properties (SUHJY), China Shenhua Energy (CSUAY), Bayerische Motoren Werke (BAMXF), Recruit (RCRRF), PERNOD RICARD S/ADR (PDRDY), SCHNEIDER ELEC /ADR (SBGSY), ORIENTAL LD CO/ADR (OLCLY), SEVEN & I HOLDI/ADR (SVNDY), CK HUTCHISON HO/ADR (CKHUY) and BK CHINA LTD/ADR (BACHY).
Who are Eisai's key executives?
Eisai's management team includes the folowing people:
- Mr. Haruo Naito, CEO, Representative Corp. Officer & Director (Age 72)
- Mr. Gary Hendler, Sr. VP & Pres of EMEA Region (Age 53)
- Dr. Lynn D. Kramer, VP and Chief Clinical Officer & Chief Medical Officer - Neurology Bus. Group (Age 69)
- Mr. Alexander Scott, VP, Chief Strategy Officer & Head of Strategy Dept. - Neurology Bus. Group
- Ms. Shaji Procida, VP and Pres & COO of Eisai Inc. (Age 48)
How do I buy shares of Eisai?
Shares of ESALY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eisai's stock price today?
One share of ESALY stock can currently be purchased for approximately $78.64.
How big of a company is Eisai?
Eisai has a market capitalization of $23.32 billion and generates $5.42 billion in revenue each year. The company earns $466.60 million in net income (profit) each year or $1.63 on an earnings per share basis. Eisai employs 10,456 workers across the globe.
What is Eisai's official website?
How can I contact Eisai?
Eisai's mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The company can be reached via phone at 813-3817-3700.
MarketBeat Community Rating for Eisai (OTCMKTS ESALY)
MarketBeat's community ratings are surveys of what our community members think about Eisai and other stocks. Vote "Outperform" if you believe ESALY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESALY will underperform the S&P 500 over the long term. You may vote once every thirty days.
